Free tool
FAERS Monitor: Aminosyn Ii 15% In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020041 or its brand name (Aminosyn Ii 15% In Plastic Container, Amino Acids). Reports on generic versions are filed under their own applications.
Reports
4
Serious
2
50% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia1
- furuncle1
- pain in extremity1
- product colour issue1
- product dispensing error1
- product odour abnormal1
- product preparation error1
- product quality issue1
- product supply issue1
- rheumatoid arthritis1
- uterine disorder1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| uterine disorder | 1 | 2258.1 | 413.4 | 563 |
| product colour issue | 1 | 1024.6 | 187.6 | 255 |
| product supply issue | 1 | 736.7 | 134.9 | 183 |
| furuncle | 1 | 663.8 | 121.6 | 165 |
| product odour abnormal | 1 | 502.1 | 92.0 | 125 |
| product preparation error | 1 | 255.9 | 46.9 | 63 |
| product dispensing error | 1 | 241.5 | 44.2 | 59 |
| rheumatoid arthritis | 1 | 46.3 | 8.5 | 11 |
| product quality issue | 1 | 38.7 | 7.1 | 9 |
| pain in extremity | 1 | 17.8 | 3.3 | 4 |
| arthralgia | 1 | 12.6 | 2.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.